<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">rsp</journal-id><journal-title-group><journal-title xml:lang="ru">Научно-практическая ревматология</journal-title><trans-title-group xml:lang="en"><trans-title>Rheumatology Science and Practice</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1995-4484</issn><issn pub-type="epub">1995-4492</issn><publisher><publisher-name>IMA-PRESS, LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14412/1995-4484-2015-607-613</article-id><article-id custom-type="elpub" pub-id-type="custom">rsp-2151</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL RESEARCH</subject></subj-group></article-categories><title-group><article-title>Исследование центральной гемодинамики с использованием катетеризации правых отделов сердца и легочной артерии у пациентов с системными заболеваниями соединительной ткани</article-title><trans-title-group xml:lang="en"><trans-title>INVESTIGATION OF CENTRAL HEMODYNAMICS VIA RIGHT HEART AND PULMONARY ARTERY CATHETERIZATION IN PATIENTS WITH SYSTEMIC CONNECTIVE TISSUE DISEASES</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Николаева</surname><given-names>Е. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Nikolaeva</surname><given-names>E. V.</given-names></name></name-alternatives><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Курмуков</surname><given-names>И. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Kurmukov</surname><given-names>I. A.</given-names></name></name-alternatives><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Юдкина</surname><given-names>Н. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Yudkina</surname><given-names>N. N.</given-names></name></name-alternatives><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Волков</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Volkov</surname><given-names>A. V.</given-names></name></name-alternatives><email xlink:type="simple">sandyvlk@yahoo.com</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБНУ Научно-исследовательский институт ревматологии им. В.А. Насоновой, Москва, Россия 115522 Москва, Каширское шоссе, 34А</institution><country>Россия</country></aff><aff xml:lang="en"><institution>V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia 34A, Kashirskoe Shosse, Moscow 115522</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2015</year></pub-date><pub-date pub-type="epub"><day>05</day><month>02</month><year>2016</year></pub-date><volume>53</volume><issue>6</issue><fpage>607</fpage><lpage>613</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Николаева Е.В., Курмуков И.А., Юдкина Н.Н., Волков А.В., 2016</copyright-statement><copyright-year>2016</copyright-year><copyright-holder xml:lang="ru">Николаева Е.В., Курмуков И.А., Юдкина Н.Н., Волков А.В.</copyright-holder><copyright-holder xml:lang="en">Nikolaeva E.V., Kurmukov I.A., Yudkina N.N., Volkov A.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://rsp.mediar-press.net/rsp/article/view/2151">https://rsp.mediar-press.net/rsp/article/view/2151</self-uri><abstract><p>Легочная артериальная гипертензия (ЛАГ), ассоциированная с системными заболеваниями соединительной ткани (СтЗСТ), является прогностически неблагоприятным проявлением последних, в отсутствие терапии приводящим к летальному исходу. Инвазивное определение параметров гемодинамики занимает главенствующее место в диагностике, определении тактики лечения и прогноза заболевания.</p><p>Цель исследования – обобщение результатов катетеризации больных с ЛАГ-СтЗСТ, поступающих в ФГБНУ НИИР им. В.А. Насоновой.</p><sec><title>Материал и методы</title><p>Материал и методы. В исследование включено 59 пациентов, госпитализированных в ФГБНУ НИИР им. В.А. Насоновой с сентября 2009 г. по сентябрь 2014 г. Диагноз ЛАГ устанавливался в соответствии с общепринятыми рекомендациями. Всем пациентам проводилась катетеризация правых отделов сердца и легочной артерии на момент установления диагноза и в динамике на фоне лечения.</p></sec><sec><title>Результаты и обсуждение</title><p>Результаты и обсуждение. Все пациенты, включенные в исследование, соответствовали критериям прекапиллярной легочной гипертензии (ЛГ): среднее давление в легочной артерии (ДЛАср) ≥25 мм рт. ст., давление заклинивания в легочной артерии (ДЗЛА) &lt;15 мм рт. ст. Исключение других причин ЛГ (легочный фиброз, патология левых отделов сердца и тромбоэмболии), а также высокий транспульмональный градиент (ТПГ) &gt;15 мм рт. ст. и легочное сосудистое сопротивление (ЛСС) &gt;3 единиц Вуда позволили диагностировать ЛАГ у всех наших пациентов. Выявлена статистически высоко значимая связь между патологическим изменением гемодинамических параметров и функциональным классом (ФК). Выявлен наиболее тесный уровень связи ФК с величиной давления в правом предсердии (ДПП), сердечным выбросом (СВ), ЛСС и ударным индексом (УИ). Из наиболее часто встречающихся проявлений сердечной недостаточности только наличие периферических отеков было связано с ухудшением гемодинамических параметров под влиянием ЛАГ. Необходимо отметить, что из двух биомаркеров (N-концевой предшественник мозгового натрийуретического пептида и мочевая кислота) первый в большей степени связан с величиной изменения гемодинамических факторов. Критические значения параметров гемодинамики были обусловлены крайней степенью выраженности задержки жидкости — анасаркой (ДПП &gt;17 мм рт. ст., ЛСС &gt;20 единиц Вуда, УИ &lt;14 мл/м2). Анализ клинико-инструментальных параметров в зависимости от ФК выявил линейную зависимость ДПП, СВ,ЛСС между уровнем этих показателей и ФК, причем наиболее высокие коэффициенты корреляции отмечались для гемодинамических показателей, характеризующих систолическую функцию правого желудочка. Примечательно, что изменений ДЛАср выявлено не было, лишь у пациентов с IV ФК отмечалось незначимое его повышение (с 51±8 до 55±8 мм рт. ст.; р=0,087). Уровень ДЗЛА оставался неизменным вне зависимости от ФК.</p></sec><sec><title>Заключение</title><p>Заключение. Таким образом, гемодинамические параметры, определяемые у пациентов с ЛАГ-СтЗСТ во время катетеризации правых отделов сердца и ЛА, тесным образом связаны с проявлениями дыхательной и сердечной недостаточностей, биомаркерами и ФК ЛАГ.</p></sec></abstract><trans-abstract xml:lang="en"><p>Pulmonary arterial hypertension (PAH) associated with systemic connective tissue diseases (SCTD) is a poor prognostic manifestation of the latter that result in death if untreated. The invasive determination of hemodynamic parameters is prominent in diagnosing the disease and determining its treatment policy and prognosis.</p><sec><title>Objective</title><p>Objective: to analyze the results of catheterization in PAH-SCTD patients admitted to the V.A. Nasonova Research Institute of Rheumatology.</p></sec><sec><title>Subjects and methods</title><p>Subjects and methods. The investigation included 59 patients admitted to the V.A. Nasonova Research Institute of Rheumatology from September 2009 to September 2014. PAH was diagnosed in accordance with the conventional guidelines. All the patients underwent right heart and pulmonary artery (PA) catheterization at the diagnosis and over time during treatment.</p></sec><sec><title>Results and discussion</title><p>Results and discussion. All the patients included in the trial met the pre-capillary pulmonary hypertension (PH) criteria: mean pulmonary artery pressure (MPAP) ≥25 mm Hg; and PA wedge pressure (PAWP) &lt;15 mm Hg. The exclusion of other causes of PH (pulmonary fibrosis, left heart disease, and thromboembolism), as well as a high transpulmonary pressure gradient &gt;15 mm Hg and pulmonary vascular resistance (PVR) &gt;3 Wood units could diagnose PAH in all our patients. There was a statistically highly significant association between pathological hemodynamic changes and functional class (FC). FC was found to be most closely correlated with right atrial pressure (RAP), cardiac output (CO), PVR, and cardiac index (CI). Among the most common manifestations of heart failure, only the presence of peripheral edemas was associated with worse hemodynamic parameters in PAH. It should be noted that out of two biomarkers (N-terminal pro-brain natriuretic peptide and uric acid), the former is largely related to the magnitude of changes in hemodynamic factors. The critical values of hemodynamic parameters were due to extreme edema – anasarca (RAP &gt;17 mm Hg, PVR &gt;20 Wood units, CI &lt;14 ml/m2). Analysis of clinical and instrumental parameters in relation to FC revealed a linear relationship of RAP, CO, and PVR between the level of these parameters and FC; moreover, the highest correlation coefficients were observed for the hemodynamic parameters characterizing right ventricular systolic function. It is remarkable that no MPAP changes were found; only patients with FC IV showed its slight increase (from 51±8 to 55±8 mm Hg; р = 0.087). PAWP remained unchanged regardless of FC.</p></sec><sec><title> </title><p> </p></sec><sec><title>Conclusion</title><p>Conclusion. Thus, the hemodynamic parameters determined in patients with PAH-SCTD during right heart and LA catheterization are closely related to the manifestations of respiratory and heart failure, the biomarkers, and FC of PAH.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>легочная артериальная гипертензия</kwd><kwd>катетеризация правых отделов сердца и легочной артерии</kwd><kwd>центральная гемодинамика</kwd><kwd>системные заболевания соединительной ткани</kwd></kwd-group><kwd-group xml:lang="en"><kwd>pulmonary arterial hypertension</kwd><kwd>right heart and pulmonary catheterization</kwd><kwd>central hemodynamics</kwd><kwd>systemic connective tissue diseases.</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Чазова ИЕ, Мартынюк ТВ, редакторы. Легочная гипертензия. Москва: Практика; 2015 [Chazova IE, Martynyuk TV, editors. Legochnaya gipertenziya [Pulmonary hypertension]. Moscow: Praktika; 2015].</mixed-citation><mixed-citation xml:lang="en">Чазова ИЕ, Мартынюк ТВ, редакторы. Легочная гипертензия. Москва: Практика; 2015 [Chazova IE, Martynyuk TV, editors. Legochnaya gipertenziya [Pulmonary hypertension]. Moscow: Praktika; 2015].</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Волков АВ. Легочная артериальная гипертензия при системных заболеваниях соединительной ткани. Научно-практическая ревматология. 2015;53(1):69–77 [Volkov AV. Pulmonary arterial hypertension in connective tissue diseases. Nauchno-prakticheskaya revmatologiya =Rheumatology Science and Practice. 2015;53(1):69–77 (In Russ.)]. doi: 10.14412/1995-4484-2015-69-77</mixed-citation><mixed-citation xml:lang="en">Волков АВ. Легочная артериальная гипертензия при системных заболеваниях соединительной ткани. Научно-практическая ревматология. 2015;53(1):69–77 [Volkov AV. Pulmonary arterial hypertension in connective tissue diseases. Nauchno-prakticheskaya revmatologiya =Rheumatology Science and Practice. 2015;53(1):69–77 (In Russ.)]. doi: 10.14412/1995-4484-2015-69-77</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Волков АВ, Мартынюк ТВ, Юдкина НН и др. Выживаемость пациентов с легочной артериальной гипертензией, ассоциированной с системной склеродермией. Терапевтический архив. 2012;(5):24–8 [Volkov AV, Martynyuk TV, Yudkina NN, et al. The survival rate of patients with pulmonary arterial hypertension associated with systemic scleroderma. Terapevticheskii arkhiv. 2012;(5):24–8 (In Russ.)].</mixed-citation><mixed-citation xml:lang="en">Волков АВ, Мартынюк ТВ, Юдкина НН и др. Выживаемость пациентов с легочной артериальной гипертензией, ассоциированной с системной склеродермией. Терапевтический архив. 2012;(5):24–8 [Volkov AV, Martynyuk TV, Yudkina NN, et al. The survival rate of patients with pulmonary arterial hypertension associated with systemic scleroderma. Terapevticheskii arkhiv. 2012;(5):24–8 (In Russ.)].</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Koh ET, Lee P, Gladman DD, Abu-Shakra M. Pulmonary hypertension in systemic sclerosis: an analysis of 17 patients. Br J Rheumatol. 1996;35:989–93. doi: 10.1093/rheumatology/35.10.989</mixed-citation><mixed-citation xml:lang="en">Koh ET, Lee P, Gladman DD, Abu-Shakra M. Pulmonary hypertension in systemic sclerosis: an analysis of 17 patients. Br J Rheumatol. 1996;35:989–93. doi: 10.1093/rheumatology/35.10.989</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Fagan KA, Badesch DB. Pulmonary hypertension associated with connective tissue disease. Prog Cardiovasc Dis. 2002;45:225–34. doi: 10.1053/pcad.2002.129975</mixed-citation><mixed-citation xml:lang="en">Fagan KA, Badesch DB. Pulmonary hypertension associated with connective tissue disease. Prog Cardiovasc Dis. 2002;45:225–34. doi: 10.1053/pcad.2002.129975</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Yang X, Mardekian K, Sanders KN, et al. Prevalence of pulmonary arterial hypertension in patients with connective tissue diseases: a systematic review of the literature. Clin Rheumatol. 2013;32:1519–31. doi: 10.1007/s10067-013-2307-2</mixed-citation><mixed-citation xml:lang="en">Yang X, Mardekian K, Sanders KN, et al. Prevalence of pulmonary arterial hypertension in patients with connective tissue diseases: a systematic review of the literature. Clin Rheumatol. 2013;32:1519–31. doi: 10.1007/s10067-013-2307-2</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Launay D, Sitbon O, Hachulla E, et al. Survival in systemic sclerosis-associated pulmonary arterial hypertension in the modern management era. Ann Rheum Dis. 2013;72:1940–6. doi: 10.1136/annrheumdis-2012-202489</mixed-citation><mixed-citation xml:lang="en">Launay D, Sitbon O, Hachulla E, et al. Survival in systemic sclerosis-associated pulmonary arterial hypertension in the modern management era. Ann Rheum Dis. 2013;72:1940–6. doi: 10.1136/annrheumdis-2012-202489</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Simonneau G, Galie N, Jansa P, et al. Long-term results from the EARLY study of bosentan in WHO functional class II pulmonary arterial hypertension patients. Int J Cardiol. 2014 Mar 15;172(2):332–9. doi: 10.1016/j.ijcard.2013.12.179</mixed-citation><mixed-citation xml:lang="en">Simonneau G, Galie N, Jansa P, et al. Long-term results from the EARLY study of bosentan in WHO functional class II pulmonary arterial hypertension patients. Int J Cardiol. 2014 Mar 15;172(2):332–9. doi: 10.1016/j.ijcard.2013.12.179</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Humbert M, Yaici A, de Groote P, et al. Screening for pulmonary arterial hypertension in patients with systemic sclerosis: clinical characteristics at diagnosis and long-term survival. Arthritis Rheum. 2011 Nov;63(11):3522–30. doi: 10.1002/art.30541</mixed-citation><mixed-citation xml:lang="en">Humbert M, Yaici A, de Groote P, et al. Screening for pulmonary arterial hypertension in patients with systemic sclerosis: clinical characteristics at diagnosis and long-term survival. Arthritis Rheum. 2011 Nov;63(11):3522–30. doi: 10.1002/art.30541</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Campo A, Mathai SC, Le Pavec J, et al. Hemodynamic predictors of survival in scleroderma-related pulmonary arterial hypertension. Am J Respir Crit Care Med. 2010 Jul 15;182(2):252–60. doi: 10.1164/rccm.200912-1820OC</mixed-citation><mixed-citation xml:lang="en">Campo A, Mathai SC, Le Pavec J, et al. Hemodynamic predictors of survival in scleroderma-related pulmonary arterial hypertension. Am J Respir Crit Care Med. 2010 Jul 15;182(2):252–60. doi: 10.1164/rccm.200912-1820OC</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Berger M, Haimowitz A, van Tosh A, et al. Quantitative assessment of pulmonary hypertension in patients with tricuspid regurgitation using continuous wave Doppler ultrasound. J Am Coll Cardiol. 1985;6:359–65. doi: 10.1016/S0735-1097(85)80172-8</mixed-citation><mixed-citation xml:lang="en">Berger M, Haimowitz A, van Tosh A, et al. Quantitative assessment of pulmonary hypertension in patients with tricuspid regurgitation using continuous wave Doppler ultrasound. J Am Coll Cardiol. 1985;6:359–65. doi: 10.1016/S0735-1097(85)80172-8</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">D’Alto M, Romeo E, Argiento P, et al. Accuracy and precision of echocardiography versus right heart catheterization for the assessment of pulmonary hypertension. Int J Cardiol. 2013;168:4058–62. doi: 10.1016/j.ijcard.2013.07.005</mixed-citation><mixed-citation xml:lang="en">D’Alto M, Romeo E, Argiento P, et al. Accuracy and precision of echocardiography versus right heart catheterization for the assessment of pulmonary hypertension. Int J Cardiol. 2013;168:4058–62. doi: 10.1016/j.ijcard.2013.07.005</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Farber HW, Foreman AJ, Miller DP, McGoon MD. REVEAL Registry: correlation of right heart catheterization and echocardiography in patients with pulmonary arterial hypertension. Congest Heart Fail. 2011;17:56–64. doi: 10.1111/j.1751-7133.2010.00202.x</mixed-citation><mixed-citation xml:lang="en">Farber HW, Foreman AJ, Miller DP, McGoon MD. REVEAL Registry: correlation of right heart catheterization and echocardiography in patients with pulmonary arterial hypertension. Congest Heart Fail. 2011;17:56–64. doi: 10.1111/j.1751-7133.2010.00202.x</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Mukerjee D, St George D, Knight C, et al. Echocardiography and pulmonary function as screening tests for pulmonary arterial hypertension in systemic sclerosis. Rheumatology (Oxford). 2004;43:461–6. doi: 10.1093/rheumatology/keh067</mixed-citation><mixed-citation xml:lang="en">Mukerjee D, St George D, Knight C, et al. Echocardiography and pulmonary function as screening tests for pulmonary arterial hypertension in systemic sclerosis. Rheumatology (Oxford). 2004;43:461–6. doi: 10.1093/rheumatology/keh067</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Galie N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. The task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J. 2009;30:2493–537. doi: 10.1093/eurheartj/ehp297</mixed-citation><mixed-citation xml:lang="en">Galie N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. The task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J. 2009;30:2493–537. doi: 10.1093/eurheartj/ehp297</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation. 2009;119:2250–94. doi: 10.1161/CIRCULATIONAHA. 109.192230</mixed-citation><mixed-citation xml:lang="en">McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation. 2009;119:2250–94. doi: 10.1161/CIRCULATIONAHA. 109.192230</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Чазова ИЕ, Авдеев СН, Царева НА и др. Клинические рекомендации по диагностике и лечению легочной гипертонии. Терапевтический архив. 2014;(9):4–23 [Chazova IE, Avdeev SN, Tsareva NA, et al. Clinical guidelines for diagnosis and treatment of pulmonary hypertension. Terapevticheskii arkhiv. 2014;(9):4–23 (In Russ.)].</mixed-citation><mixed-citation xml:lang="en">Чазова ИЕ, Авдеев СН, Царева НА и др. Клинические рекомендации по диагностике и лечению легочной гипертонии. Терапевтический архив. 2014;(9):4–23 [Chazova IE, Avdeev SN, Tsareva NA, et al. Clinical guidelines for diagnosis and treatment of pulmonary hypertension. Terapevticheskii arkhiv. 2014;(9):4–23 (In Russ.)].</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Schwaiger JP, Khanna D, Coghlan GJ. Screening patients with scleroderma for pulmonary arterial hypertension and implications for other at-risk populations. Eur Respir Rev. 2013;22:515–25. doi: 10.1183/09059180.00006013</mixed-citation><mixed-citation xml:lang="en">Schwaiger JP, Khanna D, Coghlan GJ. Screening patients with scleroderma for pulmonary arterial hypertension and implications for other at-risk populations. Eur Respir Rev. 2013;22:515–25. doi: 10.1183/09059180.00006013</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Hachulla E, Gressin V, Guillevin L, et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum. 2005;52:3792–800. doi: 10.1002/art.21433</mixed-citation><mixed-citation xml:lang="en">Hachulla E, Gressin V, Guillevin L, et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum. 2005;52:3792–800. doi: 10.1002/art.21433</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Coghlan JC, Denton CP, Grü nig E, et al. Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. Ann Rheum Dis. 2014;73:1340–9. doi: 10.1136/annrheumdis-2013-203301</mixed-citation><mixed-citation xml:lang="en">Coghlan JC, Denton CP, Grü nig E, et al. Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. Ann Rheum Dis. 2014;73:1340–9. doi: 10.1136/annrheumdis-2013-203301</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Kawut SM, Taichman DB, Archer-Chicko CL, et al. Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis. Chest. 2003;123:344–50. doi: 10.1378/chest.123.2.344</mixed-citation><mixed-citation xml:lang="en">Kawut SM, Taichman DB, Archer-Chicko CL, et al. Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis. Chest. 2003;123:344–50. doi: 10.1378/chest.123.2.344</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Benza RL, Miller DP, Gomberg-Maitland M, et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation. 2010 Jul 13;122(2):164–72. doi: 10.1161/CIRCULATIONAHA. 109.898122</mixed-citation><mixed-citation xml:lang="en">Benza RL, Miller DP, Gomberg-Maitland M, et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation. 2010 Jul 13;122(2):164–72. doi: 10.1161/CIRCULATIONAHA. 109.898122</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Mauritz GJ, Rizopoulos D, Groepenhoff H, et al. Usefulness of serial N-terminal pro-B-type natriuretic peptide measurements for determining prognosis in patients with pulmonary arterial hypertension. Am J Cardiol. 2011 Dec 1;108(11):1645–50. doi: 10.1016/j.amjcard.2011.07.025</mixed-citation><mixed-citation xml:lang="en">Mauritz GJ, Rizopoulos D, Groepenhoff H, et al. Usefulness of serial N-terminal pro-B-type natriuretic peptide measurements for determining prognosis in patients with pulmonary arterial hypertension. Am J Cardiol. 2011 Dec 1;108(11):1645–50. doi: 10.1016/j.amjcard.2011.07.025</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">McLaughlin VV, Presberg KW, Doyle R, et al. Prognosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest. 2004;126:78–92. doi: 10.1378/chest.126.1_suppl.78S</mixed-citation><mixed-citation xml:lang="en">McLaughlin VV, Presberg KW, Doyle R, et al. Prognosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest. 2004;126:78–92. doi: 10.1378/chest.126.1_suppl.78S</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
